Why Moderna Was So Volatile on Thursday

What happened

Moderna (NASDAQ: MRNA) was a roller-coaster stock on Thursday, at one point trading 3% higher, then as much as 6% lower, before settling in for a 1.3% loss at the end of the day.

A business update and several fresh pieces of news, released on the company's annual "R&D Day," left the market wondering whether such developments were collectively positive or negative for the high-profile biotech.

So what

Moderna said that its mRNA-1273 coronavirus vaccine candidate could win emergency use authorization (EUA) from the Food and Drug Administration as soon as the end of this year. If that happens, it said, it will be prepared to produce millions of doses of the vaccine. Moderna added that it has enrolled 25,296 participants for mRNA-1273's current phase 3 study, well within reach of its 30,000 goal.

Doctor writing on a patient's medical chart, with the patient in the background.

Image source: Getty Images.

Moderna also announced two new research programs; one with Vertex Pharmaceuticals (NASDAQ: VRTX) concerning gene editing treatments for patients who suffer from cystic fibrosis, and the other with Italy-based Chiesi to explore using its messenger RNA (mRNA)-based approach to battle pulmonary arterial hypertension.

Now what

Moderna stands to reap as much as $455 million in the Vertex collaboration, and $425 million for the Chiesi arrangement; neither figure counts potential royalties from sales.

However, investors might be concerned that the company is losing focus on developing mRNA-1273. After all, it's not only the most important project for it as a company, it's the most important for the health of the world just now.

10 stocks we like better than Moderna INC
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna INC wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of August 1, 2020


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More